| scholarly article | Q13442814 |
| P2093 | author name string | Christopher P Denton | |
| Dinesh Khanna | |||
| Oliver Distler | |||
| Peter A Merkel | |||
| Daniel E Furst | |||
| Lorinda Chung | |||
| Scleroderma Clinical Trials Consortium | |||
| P433 | issue | 2 Suppl 71 | |
| P304 | page(s) | S97-102 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Clinical and Experimental Rheumatology | Q15759225 |
| P1476 | title | Clinical trial design in scleroderma: where are we and where do we go next? | |
| P478 | volume | 30 |
| Q58736202 | A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol |
| Q28080323 | Cellular Therapies in Systemic Sclerosis: Recent Progress |
| Q51137555 | Clinical efficacy and safety of bathing with Chinese medicine Taohong Siwu Decoction () for treatment of diffuse cutaneous systemic sclerosis: A randomized, placebo-controlled trial. |
| Q35804073 | Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis |
| Q38749200 | Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis |
| Q92945989 | Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis |
| Q38379767 | Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. |
| Q38097276 | Targeted therapies for systemic sclerosis |
| Q36758822 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q40002833 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q37465397 | Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial |
Search more.